Last reviewed · How we verify
Merrem (Meropenem)
Meropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
Merrem (Meropenem) is a carbapenem antibiotic developed by AstraZeneca and currently owned by Hq Spclt Pharma. It is a small molecule that targets a wide range of bacteria, including those resistant to other antibiotics. Merrem is approved to treat various infections, including abdominal abscess, bacterial meningitis, and complicated skin and skin structure infections. The drug is off-patent, with multiple generic manufacturers available. Key safety considerations include its short half-life and low bioavailability.
At a glance
| Generic name | Meropenem |
|---|---|
| Sponsor | Pfizer |
| Drug class | meropenem |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1996 |
Mechanism of action
VABOMERE is an antibacterial drug [see Microbiology (12.4)].
Approved indications
- Abdominal abscess
- Bacterial meningitis
- Bacteroides Complicated Appendicitis
- Bacteroides Peritonitis
- Complicated Skin and Skin Structure Infection
- Complicated appendicitis
- E. Coli Complicated Appendicitis
- E. Coli Peritonitis
- H. Influenzae Meningitis
- Infection due to Pseudomonas aeruginosa
- Infectious disease of abdomen
- Klebsiella Complicated Appendicitis
- Klebsiella Pneumoniae Peritonitis
- Neisseria meningitidis meningitis
- Peptostreptococcus Complicated Appendicitis
- Peptostreptococcus Peritonitis
- Peritonitis
- Pneumococcal meningitis
- Pseudomonas Aeruginosa Complicated Appendicitis
- Streptococcal Peritonitis
Common side effects
- Diarrhea
- Nausea
- Constipation
- Headache
- Anemia
- Pain
- Rash
- Vomiting
- Phlebitis/thrombophlebitis
- Inflammation at the injection site
- Injection site reaction
- Edema at the injection site
Drug interactions
- valproic acid
Key clinical trials
- Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1,PHASE2)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Merrem CI brief — competitive landscape report
- Merrem updates RSS · CI watch RSS
- Pfizer portfolio CI